Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms

Leukemia and Lymphoma

Volumn 53, Issue 3, 2012, Pages 441-444

  Johansson, Peter ^a,b   Mesa, Ruben ^c   Scherber, Robyn ^d   Abelsson, Johanna ^a   Samuelsson, Jan ^e   Birgegård, Gunnar ^f   Andréasson, Björn ^a,b  

^a NU Hospital Organization   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c MAYO CLINIC   (United States)

^d ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^e STOCKHOLM SÖDER HOSPITAL   (Sweden)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Myeloproliferative neoplasms; Quality of life

Indexed keywords

HEMOGLOBIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; AGING; ARTICLE; BONE PAIN; COHORT ANALYSIS; COUGHING; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; FATIGUE; FEMALE; FEVER; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSOMNIA; MALE; MENTAL CONCENTRATION; MOOD; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM SYMPTOM ASSESSMENT FORM; NIGHT SWEAT; PARESTHESIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; SATIETY; SEX DIFFERENCE; SEXUAL DYSFUNCTION; THROMBOCYTHEMIA; WEIGHT REDUCTION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANOREXIA; FATIGUE; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; MYELOPROLIFERATIVE DISORDERS; NERVOUS SYSTEM DISEASES; PAIN; QUALITY OF LIFE; QUESTIONNAIRES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SWEDEN; WEIGHT LOSS;

EID: 84857512891     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.619608     Document Type: Article

References (15)

1. Th iele J, Kvasnicka HM. Th e 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofi brosis. Curr Hematol Malig Rep 2009;4:33-40.
2. Abdulkarim K, Girodon F, Johansson P.et al. AML transformation in 56 patients with Ph- MPD in two well defi ned populations. Eur. J. Haematol. 2009;82:106-111.
3. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008;22:905-914. (Pubitemid 351698623)
4. V annucchi AM. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Int Emerg Med 2010;5:177-184.
5. Mesa RA, Niblack J, Wadleigh M.et al. Th e burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international internet-based survey of 1179 MPD patients. Cancer 2007;109:68-76. (Pubitemid 46120195)
6. Merup M, Aberg W, Lofvenberg E.et al. Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferonalpha. Acta Oncol 2002;41:50-55. (Pubitemid 34293359)
7. Samuelsson J, Hasselbalch H, Bruserud O.et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: Feasibility, clinical and biologic eff ects, and impact on quality of life. Cancer 2006;106:2397-2405. (Pubitemid 43787664)
8. Aaronson NK, Ahmedzai S, Bergman B.et al. Th e European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 1993;85:365-376. (Pubitemid 23073154)
9. Scherber R, Dueck AC, Johansson P.et al. Th e Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients. Blood 2011;118:401-408.
10. M esa RA, Schwager S, Radia D.et al. Th e Myelofi brosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofi brosis. Leuk Res 2009;33:1199-1203.
11. Wild D, Grove A, Martin M.et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR task force for translation and cultural adaptation. Value Health 2005;8:94-104. (Pubitemid 40525371)
12. Mendoza TR, Wang XS, Cleeland CS.et al. Th e rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999;85:1186-1196. (Pubitemid 29115600)
13. M ichelson H, Bolund C, Brandberg Y. Multiple chronic health problems are negatively associated with health related quality of life (HRQoL) irrespective of age. Qual Life Res 2000;9:1093-1104. (Pubitemid 32452953)
14. Hjermstad MJ, Fayers PM, Bjordal K.et al. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: The QLQ= C30 + 3. J. Clin. Oncol. 1998;16:1188-1196. (Pubitemid 28108757)
15. S chwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur. J. Cancer 2001;37:1345-1351. (Pubitemid 32588744)